| Literature DB >> 31127356 |
Augusto Quaresma Pedro1,2, João António Queiroz1, Luís António Passarinha3,4.
Abstract
Membrane proteins (MP) constitute 20-30% of all proteins encoded by the genome of various organisms and perform a wide range of essential biological functions. However, despite they represent the largest class of protein drug targets, a relatively small number high-resolution 3D structures have been obtained yet. Membrane protein biogenesis is more complex than that of the soluble proteins and its recombinant biosynthesis has been a major drawback, thus delaying their further structural characterization. Indeed, the major limitation in structure determination of MP is the low yield achieved in recombinant expression, usually coupled to low functionality, pinpointing the optimization target in recombinant MP research. Recently, the growing attention that have been dedicated to the upstream stage of MP bioprocesses allowed great advances, permitting the evolution of the number of MP solved structures. In this review, we analyse and discuss effective solutions and technical advances at the level of the upstream stage using prokaryotic and eukaryotic organisms foreseeing an increase in expression yields of correctly folded MP and that may facilitate the determination of their three-dimensional structure. A section on techniques used to protein quality control and further structure determination of MP is also included. Lastly, a critical assessment of major factors contributing for a good decision-making process related to the upstream stage of MP is presented.Entities:
Keywords: Codon usage; Host; Membrane protein; Optimization; Production; Protein 3D-structure; Quality control; Structure determination
Mesh:
Substances:
Year: 2019 PMID: 31127356 PMCID: PMC7079970 DOI: 10.1007/s00253-019-09873-1
Source DB: PubMed Journal: Appl Microbiol Biotechnol ISSN: 0175-7598 Impact factor: 4.813
Major advantages, limitations, and general characteristics of recombinant membrane protein expression systems
| Host | Advantages | Drawbacks | Other characteristics | References |
|---|---|---|---|---|
Gram-negative bacterium | Inexpensive; rapid generation of expression plasmids; fast growth; easy scale up; simple culture requirements | Endotoxin; inclusion body formation; inefficient protein secretion; many MP do not fold properly; lack of efficient PTM; unable to efficiently express proteins larger than 120 kDa | Specific strains (e.g., Lemo21) or introduction of solubility tags may improve MP expression. Inner membrane and the inner leaflet of the outer membrane are mainly composed by phosphatidylethanolamine followed by phosphatidylglycerol and few cardiolipin and the outer leaflet of the outer membrane is highly enriched in Lipopolysaccharide | (Bernaudat et al. |
Methylotrophic yeast; GRAS organism | Efficient protein secretion with low levels of endogenous proteins. Capable of performing many PTM; low cost of culture media; industry-scale fermentation | Glycosylation pattern different from mammalian; intracellular recovery of large amount of cells may require specific equipment (French-press); high oxygen demand | Improved glyco-engineered strains obtained using the GlycoSwitch® technology; wide range of genetic tools, plasmids, strains, and promoters available; the preference for the respiratory growth allow to be cultivated at high cell densities. Plasma membrane composed of phospholipids, sterols (ergosterol), and sphingolipids (inositol) | (Gonçalves et al. |
Insect cells Baculovirus-infected cells | More native environment than yeast; more compatible with eukaryotic MP because of similar codon usage rules than | Cost; non-native glycosylation and lipid environment; cell lysis; some of the PTM are not identical to those found in mammalian; long production time; relative high media costs | Used for MP expression as a compromise between bacterial and mammalian systems. Viral infection promote cell lysis and may lead to proteolysis of target protein | (Bernaudat et al. |
Mammalian cells Stable integration and transient transfection | Proper folding; stable/transient folding; native lipid environment and post-translational pathways | High media costs; slow growth rates; low expression; viral infection; cost; higher technical requirements | For particular targets, may be the only expression system able to express a given MP in a functional and properly folded state. Cholesterol present in membranes may be essential for the functionality of certain MP | (Midgett and Madden |
| Cell-free expression | Short time reaction; manipulation of reaction conditions allow to control conveniently the PTM; plasmid or DNA can be directly used for protein expression; special proteins can be expressed with a composition of non-natural amino acids | High costs, low protein production rates; insufficiency of PTM is a bottleneck to obtain complex proteins in a functional form | May be based in prokaryotic or eukaryotic CF systems; MP may be produced co-translationally in artificial membrane environments | (Rajesh et al. |
Fig. 1Overview of the topics included in this review amenable to optimization and, thus, relevant for obtaining a successful strategy for recombinant MP biosynthesis
Critical assessment of major parameters affecting the upstream stage of recombinant MP structural biology projects for a good decision-making process.
| Parameter |
|
| Mammalian cell lines | ||
|---|---|---|---|---|---|
| Transiently transfected | Stable clones | ||||
| Gene dosage | Preference: Plasmid-based system with medium-high PCN | Mixed results, screening is advisable; higher gene dosage can increase yield | Usually favored by high gene dosage | ||
| Codon optimization | Advisable testing for heterologous targets; “optimized” or “harmonized” codons often lead to outstanding improvements | ||||
| Cost | Very low | Low | Very high | ||
| Ease of manipulation/labor intensive | High/Low | High/Low | Low/High | Low/Very High | |
| Scalability | Very good | Very good | Moderate | ||
| Timescale | Days | Week | Days/Week | Lengthy (months) | |
| Membrane protein features | Glycosylation | Low/Absent | High1 | Very high | |
| Other PTM | Bad | Good | Very good | ||
| Lipid composition | Bad | Good2 | Very good | ||
| Specific organelles requirements (e.g. mitochondria) | Bad | Bad | Good | ||
| Molecular weight | Limited | Good | Good | ||
| Protein productivity | Good | Very good | Bad | ||
| Observations | The source from which more MP structures were solved3 | Viable alternative to mammalian and insect cells for obtaining low cost and high yield of MP | The most complete for human MP expression, greatly exemplified by SERT4 | ||
1Using the GlycoSwitch® technology (Laukens et al., 2015); 2Humanized pathway (Hirz et al., 2013); 3Pandey et al., 2016; 4Andréll and Tate, 2013.
Fig. 2Schematic diagram of MP structure determination pipeline focusing relevant parameters to optimize their upstream stage and techniques used to protein quality control